• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[ASAS/EULAR关于强直性脊柱炎管理的建议:德语区2010年更新版评估]

[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].

作者信息

Kiltz U, Sieper J, Braun J

机构信息

Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, 44652, Herne.

出版信息

Z Rheumatol. 2013 Feb;72(1):71-80. doi: 10.1007/s00393-012-1071-z.

DOI:10.1007/s00393-012-1071-z
PMID:23223873
Abstract

The ASAS/EULAR recommendations for the management of ankylosing spondylitis have been updated in 2010. The recommendations have been extended from 10 to 11 recommendations and 4 superior principles have been introduced based on the level of evidence and expert knowledge. The recommendations have been translated into German and have been evaluated by 25 experts from Germany, Austria and Switzerland. The experts scored the strength of the recommendations (SOR) on an 11 point numerical rating scale (from 0 = no agreement to 10 = total agreement). With a mean score of 9.6 ± 1.05 the SOR was generally very good.

摘要

2010年,强直性脊柱炎评估国际工作组(ASAS)/欧洲抗风湿病联盟(EULAR)关于强直性脊柱炎管理的建议进行了更新。建议从10条扩展至11条,并根据证据水平和专家知识引入了4条高级原则。这些建议已被翻译成德语,并由来自德国、奥地利和瑞士的25位专家进行评估。专家们采用11分数字评分量表(从0分=无共识至10分=完全共识)对建议的强度(SOR)进行评分。SOR的平均得分为9.6±1.05,总体情况非常好。

相似文献

1
[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].[ASAS/EULAR关于强直性脊柱炎管理的建议:德语区2010年更新版评估]
Z Rheumatol. 2013 Feb;72(1):71-80. doi: 10.1007/s00393-012-1071-z.
2
[ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area].
Z Rheumatol. 2013 Feb;72(1):81-8. doi: 10.1007/s00393-012-1089-2.
3
[Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe].[欧洲强直性脊柱炎管理的ASAS/EULAR建议的传播与评估]
Z Rheumatol. 2009 Jul;68(5):417-9. doi: 10.1007/s00393-009-0464-0.
4
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.2010 年更新的 ASAS/EULAR 强直性脊柱炎治疗建议。
Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027.
5
[Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].[德国版ASAS/EULAR强直性脊柱炎管理推荐的患者评估]
Z Rheumatol. 2008 Dec;67(8):694-700, 702. doi: 10.1007/s00393-008-0371-9.
6
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].[ASAS/EULAR 之后强直性脊柱炎管理的建议。德语区的评估]
Z Rheumatol. 2006 Dec;65(8):728-42. doi: 10.1007/s00393-006-0119-3.
7
[German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].[强直性脊柱炎管理的ASAS/EULAR建议的德语患者版本]
Z Rheumatol. 2010 Mar;69(2):171-4, 176-9. doi: 10.1007/s00393-009-0428-4.
8
[EULAR recommendations for patient education of people with inflammatory arthritis. Translation and evaluation in Germany].[欧洲抗风湿病联盟关于炎性关节炎患者教育的建议。在德国的翻译与评估]
Z Rheumatol. 2016 Mar;75(2):187-99. doi: 10.1007/s00393-015-0020-z.
9
Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists.强直性脊柱炎管理的ASAS/EULAR建议的传播与评估:1507名风湿病学家的研究结果
Ann Rheum Dis. 2008 Jun;67(6):782-8. doi: 10.1136/ard.2007.080077. Epub 2007 Nov 29.
10
[Treatment guidelines for ankylosing spondylitis and its effect on Mexican rheumatology].[强直性脊柱炎治疗指南及其对墨西哥风湿病学的影响]
Gac Med Mex. 2009 Jan-Feb;145(1):41-9.

引用本文的文献

1
Relationship of CARD8 Gene Polymorphisms with Susceptibility to Ankylosing Spondylitis: A Case-Control Study.CARD8 基因多态性与强直性脊柱炎易感性的关系:一项病例对照研究。
Med Sci Monit. 2020 Feb 21;26:e916935. doi: 10.12659/MSM.916935.
2
The comparative efficacy of supervised- versus home-based exercise programs in patients with ankylosing spondylitis: A meta-analysis.强直性脊柱炎患者中监督式与家庭式锻炼计划的比较疗效:一项荟萃分析。
Medicine (Baltimore). 2020 Feb;99(8):e19229. doi: 10.1097/MD.0000000000019229.
3
The comparative efficacy of group- versus home-based exercise programs in patients with ankylosing spondylitis: Protocol for a meta-analysis.

本文引用的文献

1
First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.非药物治疗和非生物制剂治疗强直性脊柱炎的当前证据首次更新:强直性脊柱炎ASAS/EULAR管理建议的系统文献综述
Rheumatology (Oxford). 2012 Aug;51(8):1388-96. doi: 10.1093/rheumatology/kes066. Epub 2012 Apr 17.
2
Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?非放射性轴性脊柱关节炎患者与强直性脊柱炎患者有何不同?
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1415-22. doi: 10.1002/acr.21688.
3
强直性脊柱炎患者中团体运动与家庭运动项目的比较疗效:一项荟萃分析方案
Medicine (Baltimore). 2018 Jul;97(29):e11540. doi: 10.1097/MD.0000000000011540.
4
Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population.在中国人群中,降低重组人肿瘤坏死因子抑制剂(依那西普)的剂量对患有髋关节滑膜炎的强直性脊柱炎患者可能有效。
Int J Immunopathol Pharmacol. 2016 Sep;29(3):510-5. doi: 10.1177/0394632016656013. Epub 2016 Jul 5.
5
[What is ascertained in the therapy of axial spondyloarthritis?].[在中轴型脊柱关节炎治疗中已明确的是什么?]
Internist (Berl). 2013 Dec;54(12):1450-8. doi: 10.1007/s00108-013-3331-7.
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
依那西普与柳氮磺胺吡啶治疗强直性脊柱炎患者的临床疗效及安全性:一项随机双盲试验
Arthritis Rheum. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223.
4
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.2010 年强直性脊柱炎评估与治疗方法国际协会(ASAS)关于抗 TNF 药物治疗中轴型脊柱关节炎的推荐更新。
Ann Rheum Dis. 2011 Jun;70(6):905-8. doi: 10.1136/ard.2011.151563.
5
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.2010 年更新的 ASAS/EULAR 强直性脊柱炎治疗建议。
Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027.
6
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial.依那西普与柳氮磺吡啶治疗早期中轴型脊柱关节炎对全身 MRI 显示活动性炎症病灶的疗效:一项 48 周随机对照试验(ESTHER)
Ann Rheum Dis. 2011 Apr;70(4):590-6. doi: 10.1136/ard.2010.139667.
7
Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis.依那西普联合强化水疗康复方案治疗活动期强直性脊柱炎。
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1125-9. doi: 10.1177/039463200902200430.
8
Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis.强直性脊柱炎患者的动脉粥样硬化前期加速迹象。
J Rheumatol. 2010 Jan;37(1):161-6. doi: 10.3899/jrheum.090667. Epub 2009 Dec 1.
9
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.EULAR 基于证据的类风湿关节炎和其他形式炎症性关节炎患者心血管风险管理建议。
Ann Rheum Dis. 2010 Feb;69(2):325-31. doi: 10.1136/ard.2009.113696. Epub 2009 Sep 22.
10
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.磁共振成像(MRI)上活动性骶髂关节炎的定义用于轴向型脊柱关节炎的分类:ASAS/OMERACT MRI小组的共识方法。
Ann Rheum Dis. 2009 Oct;68(10):1520-7. doi: 10.1136/ard.2009.110767. Epub 2009 May 18.